New anti Obesity Drug on the anvil gets mixed response

September 1, 2005

The novel anti-obesity drug Acomplia weighed on shares as a French group reported mixed response to the drug along with other such drugs in its pipeline. The weight loss medication also helps people quit smoking.

Acomplia is expected to reach the market in 2006 and some analysts see it as a $3billion a year seller. Worries over the commercial potential and competition issues can leave doubts over the future growth at the company which also faces patent challenges to key drugs. The US centers for Medicare and Medicare services recently stated that it would not pay for obesity drugs and this came as a big blow to Acomplia.

For more information read:
http://today.reuters.com